Previous studies have demonstrated that delivery of human tissue kallikrein gene, protein or peptide protects against cerebral ischemia/reperfusion (I/R) injury through inhibition of oxidative stress and apoptosis, enhancement of glial cell survival, and migration and promotion of angiogenesis and neurogenesis [29, 30]. The gene discussed is KLK1; the disease is brain ischemia.